May 31, 2017 11:37 am UTC| Business
Designation Covers Broad Treatment of Epidermolysis Bullosa (EB) Top-Line Phase 3 Data on Track for 3Q17 CRANBURY, N.J., May 31, 2017 -- Amicus Therapeutics, Inc.(Nasdaq:FOLD), has received Rare Pediatric Disease...
May 31, 2017 11:37 am UTC| Business
Designation Covers Broad Treatment of Epidermolysis Bullosa (EB) Top-Line Phase 3 Data on Track for 3Q17 CRANBURY, N.J., May 31, 2017 -- Amicus Therapeutics, Inc.(Nasdaq:FOLD), has received Rare Pediatric Disease...
May 31, 2017 11:37 am UTC| Business
Designation Covers Broad Treatment of Epidermolysis Bullosa (EB) Top-Line Phase 3 Data on Track for 3Q17 CRANBURY, N.J., May 31, 2017 -- Amicus Therapeutics, Inc.(Nasdaq:FOLD), has received Rare Pediatric Disease...
May 31, 2017 11:36 am UTC| Business
- Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in potentially expanding...
May 31, 2017 11:36 am UTC| Business
- Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in potentially expanding...
May 31, 2017 11:36 am UTC| Business
- Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in potentially expanding...
May 31, 2017 11:36 am UTC| Business
- Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in potentially expanding...
India–US Trade Pact 2026: A New Highway to a USD 500 Billion Partnership